Spruce Biosciences, Inc.
$69.89
▲
1.39%
2026-04-21 09:34:01
sprucebio.com
NCM: SPRB
Explore Spruce Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$96.45 M
Current Price
$69.89
52W High / Low
$240 / $4.28
Stock P/E
—
Book Value
$30.99
Dividend Yield
—
ROCE
-85.04%
ROE
-1.09%
Face Value
—
EPS
$-50.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
3.68
Debt / Equity
1.73
Current Ratio
5.17
Quick Ratio
5.17
Forward P/E
-11.38
Price / Sales
—
Enterprise Value
$39.13 M
EV / EBITDA
-1.37
EV / Revenue
—
Rating
None
Target Price
$198.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Oramed Pharmaceuticals Inc. | $3.83 | 3.45 | $151.27 M | 0% | -7.12% | 37.1% | $3.96 / $1.98 | $4.98 |
| 2. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
| 3. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 4. | Vir Biotechnology, Inc. | $11.09 | — | $1.72 B | — | -52.69% | -45.73% | $10.94 / $4.16 | $5.49 |
| 5. | Nautilus Biotechnology, Inc. | $2.96 | — | $383.49 M | — | -36.49% | -32.27% | $4.31 / $0.62 | $1.24 |
| 6. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 7. | Rallybio Corporation | $8.29 | — | $43.48 M | — | -56.97% | -15.01% | $11.49 / $1.9 | $10.97 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0.7 M | — |
| Operating Profit | -11.1 M | -8.23 M | -2.69 M | -14.49 M | -24.07 M | — |
| Net Profit | -14.65 M | -8.21 M | -2.07 M | -14.04 M | -23.56 M | — |
| EPS in Rs | -10.67 | -5.99 | -1.51 | -10.23 | -17.17 | -15.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 4.91 M | 10.09 M | 0 M |
| Operating Profit | -36.51 M | -56.15 M | -51.99 M | -47.28 M |
| Net Profit | -38.97 M | -53.04 M | -47.92 M | -46.18 M |
| EPS in Rs | -28.4 | -38.65 | -34.93 | -33.66 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 53.02 M | 45.21 M | 103.95 M | 85.65 M |
| Total Liabilities | 10.51 M | 16.39 M | 27.44 M | 17.16 M |
| Equity | 42.52 M | 28.82 M | 76.51 M | 68.49 M |
| Current Assets | 52.11 M | 44.21 M | 102.18 M | 83.61 M |
| Current Liabilities | 10.09 M | 15.25 M | 24.46 M | 12.45 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -33.33 M | -55.96 M | -33.27 M | -41.68 M |
| Investing CF | — | 0 M | 55.78 M | 23.69 M |
| Financing CF | 43.48 M | -1.62 M | 49.14 M | -0.24 M |
| Free CF | -33.33 M | -55.96 M | -33.28 M | -41.69 M |
| Capex | — | — | -0.01 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -51.32% | — | — | — |
| Earnings Growth % | -10.68% | -3.77% | — | — |
| Profit Margin % | -1079.94% | -474.96% | — | — |
| Operating Margin % | -1143.37% | -515.34% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1072.76% | -469.48% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-07 | 1:0.0133333 |
| 2025-08-05 | 1:0.0133333 |